Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Резистин и диабетическая кардиомиопатия: патогенетические взаимосвязи
Александров Ан.А., Шацкая О.А., Кухаренко С.С., Ядрихинская М.Н., Абдалкина Е.Н., Дроздова Е.Н., Шестакова М.В. Резистин и диабетическая кардиомиопатия: патогенетические взаимосвязи. Consilium Medicum. 2014; 16 (10): 109–116.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Bore JS, Schuleri K. Myocardial remodeling: phsysiologicfl and pathological. In: Greenberg B, ed. Myocardial remedial mechanisms and treatment. New York: Taylor and Francis, 2006; p. 121–38.
2. Hein S, Arnon E, Kostin S et al. Progression from compensated hepertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 2003; 107: 984–91.
3. Leiden J. The genetics of dilated cardiomyopathy: emerging clue to the puzzle. N Engl J Med 1997; 337: 1080–1.
4. Towbin JA. Role of cytoskeletal proteins in cardiomyopathies. Curr Opin Cell Biol 1998; 10: 131–9.
5. Bowles NE, Bowles KP, Towbin JA. The «final common pathway» hypothesis and inherited cardiovascular disease: the role of cytoskeletal proteins in dilated cardiomyopathy. Herz 2000; 25: 168–75.
6. Eghbali M, Tomek R, Woods C et al. Cardiac fibroblasts are predisposed to convert into myocite phenotype: specific effect of TGFb. Proc Natl Acad Sci USA 1991; 88: 795–9.
7. Tyagi SC, Lewis K, Pikes D et al. Stretch-induced membrane type matrix metalloproteinase and tissue plasminogen activator in cardiac fibroblast cells. J Cell Phуsiol 1998; 176: 734–82.
8. Hess OM, Schneider J, Koch R et al. Diastolic function and myocardial structure in patients with myocardial hypertrophy. Circulation 1981; 63: 360–71.
9. Ding Q, Chai H, Mahmood N et al. Matrix metalloproteinases modulated by protein kinase Cε mediate resistin-induced migration of human coronary artery smooth muscle cells. J Vasc Surg 2011;
53 (4): 1044–51.
10. Kang S, Chemaly ER, Hajjar RJ, Lebeche D. Resistin Promotes Cardiac Hypertrophy via the AMP-activated Protein Kinase/Mammalian Target of Rapamycin (FMPK/mTOR) and c-Jun N-terminal Kinase/Insulin Receptor Substrate 1(JNK/IRS1) pathways. J Biol Chem 201; 286 (21): 18465–73.
11. Kim M, Oh JK, Sacata S et al. Role of Resistin in Cardiac Contractility and Hypertention. J Moll Cell Cardiol 2008; 45 (2): 270–80.
12. Park H, Ahima RS. Resistin in Rodens and Humans. Diabetes Metab J 2013; 37 (6): 404–14.
13. Menzaghi C, Bacci S, Salvemini L et al. Serum Resistin, Cardiovascular Disease and All-Cause Mortality in Patients with Type 2 Diabetes. PloS ONE 2013; 8 (6): e64729. Doi:10,1371/journal.pone.0064729.
14. Boudina S, Abel ED. Diabetic Cardiomyopathy Revisited. Circulation 2007; 115: 3213–23.
15. Chemaly ER, Hadri L, Zhang S et al. Long-term in vivo Resistin Overexpression Induces Myocardial Dysfunction and Remodeling in Rats. J Moll Cell Cardiol 2011; 51 (2): 144–55.
16. Ganau A, Devereux RB, Roman MJ et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertention. J Am Coll Cardio 1992; 19: 1550–8.
2. Hein S, Arnon E, Kostin S et al. Progression from compensated hepertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 2003; 107: 984–91.
3. Leiden J. The genetics of dilated cardiomyopathy: emerging clue to the puzzle. N Engl J Med 1997; 337: 1080–1.
4. Towbin JA. Role of cytoskeletal proteins in cardiomyopathies. Curr Opin Cell Biol 1998; 10: 131–9.
5. Bowles NE, Bowles KP, Towbin JA. The «final common pathway» hypothesis and inherited cardiovascular disease: the role of cytoskeletal proteins in dilated cardiomyopathy. Herz 2000; 25: 168–75.
6. Eghbali M, Tomek R, Woods C et al. Cardiac fibroblasts are predisposed to convert into myocite phenotype: specific effect of TGFb. Proc Natl Acad Sci USA 1991; 88: 795–9.
7. Tyagi SC, Lewis K, Pikes D et al. Stretch-induced membrane type matrix metalloproteinase and tissue plasminogen activator in cardiac fibroblast cells. J Cell Phуsiol 1998; 176: 734–82.
8. Hess OM, Schneider J, Koch R et al. Diastolic function and myocardial structure in patients with myocardial hypertrophy. Circulation 1981; 63: 360–71.
9. Ding Q, Chai H, Mahmood N et al. Matrix metalloproteinases modulated by protein kinase Cε mediate resistin-induced migration of human coronary artery smooth muscle cells. J Vasc Surg 2011;
53 (4): 1044–51.
10. Kang S, Chemaly ER, Hajjar RJ, Lebeche D. Resistin Promotes Cardiac Hypertrophy via the AMP-activated Protein Kinase/Mammalian Target of Rapamycin (FMPK/mTOR) and c-Jun N-terminal Kinase/Insulin Receptor Substrate 1(JNK/IRS1) pathways. J Biol Chem 201; 286 (21): 18465–73.
11. Kim M, Oh JK, Sacata S et al. Role of Resistin in Cardiac Contractility and Hypertention. J Moll Cell Cardiol 2008; 45 (2): 270–80.
12. Park H, Ahima RS. Resistin in Rodens and Humans. Diabetes Metab J 2013; 37 (6): 404–14.
13. Menzaghi C, Bacci S, Salvemini L et al. Serum Resistin, Cardiovascular Disease and All-Cause Mortality in Patients with Type 2 Diabetes. PloS ONE 2013; 8 (6): e64729. Doi:10,1371/journal.pone.0064729.
14. Boudina S, Abel ED. Diabetic Cardiomyopathy Revisited. Circulation 2007; 115: 3213–23.
15. Chemaly ER, Hadri L, Zhang S et al. Long-term in vivo Resistin Overexpression Induces Myocardial Dysfunction and Remodeling in Rats. J Moll Cell Cardiol 2011; 51 (2): 144–55.
16. Ganau A, Devereux RB, Roman MJ et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertention. J Am Coll Cardio 1992; 19: 1550–8.
Авторы
Ан.А.Александров1, О.А.Шацкая1, С.С.Кухаренко1, М.Н.Ядрихинская1, Е.Н.Абдалкина2, Е.Н.Дроздова1, М.В.Шестакова1
1. ФГБУ Эндокринологический научный центр Минздрава России, Москва;
2. НОУ ВПО Медицинский институт «Реавиз», Самара
1. ФГБУ Эндокринологический научный центр Минздрава России, Москва;
2. НОУ ВПО Медицинский институт «Реавиз», Самара
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.